Table 1 Molecular characteristics
From: Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion
No | Age at initial diagnosis | Histological diagnosis | Contrast enhancement | Fusion | TERT promoter | Chr + 7/− 10 | WHO 2021 | Hierarchical clustering | t-SNE cluster | MC v11b4 | CS v11 | MC v12.5 | CS v12.5 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
#01 | 56 | GB | Present | FGFR3(ex18)::TACC3(int6) | Mutated | Present | GB IDH-WT | Group 2 | GB | Glioblastoma IDH wildtype | 0.99 | GB_RTK2 | 0.94 |
#02 | 44 | GB | Present | FGFR3(ex17)::TACC3(ex11) | Mutated | Present | GB IDH-WT | Group 2 | GB | Glioblastoma IDH wildtype | 0.99 | GB_RTK2 | 0.57 |
#03 | 65 | LGG | Present | FGFR3(ex17)::TACC3(ex4) | Mutated | Present | GB IDH-WT | Group 2 | GB | Glioblastoma IDH wildtype | 0.99 | GB_MES_TYP | 0.65 |
#04 | 63 | GB | Present | FGFR3(ex17)::TACC3(ex10) | Mutated | Present | GB IDH-WT | Group 2 | GB | Glioblastoma IDH wildtype | 0.99 | GB_MES_TYP | 0.97 |
#05 | 58 | GB | Present | FGFR3(ex17)::TACC3(ex8) | Mutated | Present | GB IDH-WT | Group 4 | GB | Glioblastoma IDH wildtype | 0.99 | GG | 0.36 |
#06 | 68 | GB | Present | FGFR3(ex17)::TACC3(ex11) | Mutated | Present | GB IDH-WT | Group 3 | GB | Glioblastoma IDH wildtype | 0.71 | GB_MES_TYP | 0.81 |
#07 | 56 | LGG | No | FGFR3(ex17)::TACC3(ex11) | Mutated | Absent | GB IDH-WT | Group 4 | GB | Glioblastoma IDH wildtype | 0.90 | GG | 0.54 |
#08 | 60 | GB | Present | FGFR3(ex17)::TACC3(ex11) | Mutated | Present | GB IDH-WT | Group 3 | GB | Glioblastoma IDH wildtype | 0.85 | GB_MES_TYP | 0.89 |
#09 | 77 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Mutated | Present | GB IDH-WT | Group 3 | GB | Glioblastoma IDH wildtype | 0.67 | GB_MES_TYP | 0.84 |
#10 | 45 | LGG | NA | FGFR3(ex17)::TACC3(ex11) | Mutated | Absent | GB IDH-WT | Group 3 | GB | plexus tumor | 0.39 | GB_MES_TYP | 0.31 |
#11 | 41 | GB | Present | FGFR3(ex17)::TACC3(ex11) | Mutated | Present | GB IDH-WT | Group 4 | GB | NM | < 0.3 | GG | 0.23 |
#12 | 24 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Mutated | Present | GB IDH-WT | Group 4 | GB | LGG, GG | 0.13 | GG | 0.41 |
#12bis | NA | LGG | NA | FGFR3(ex17)::TACC3(ex10) | Mutated | Present | GB IDH-WT | Group 4 | GB | Glioblastoma IDH wildtype | 0.74 | GG | 0.61 |
#13 | 4 | LGG | Present | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 3 | GG | NM | < 0.3 | IHG | 0.26 |
#14 | 12 | LGG | No | FGFR3(ex17)::TACC3(ex13) | Wildtype | Absent | PLGG | Group 3 | GG | LGG, GG | 0.99 | GG | 0.99 |
#15 | 72 | LGG | Present | FGFR3(ex17)::TACC3(ex11) | Mutated | Absent | GB IDH-WT | Group 3 | GG | LGG, GG | 0.70 | GG | 0.99 |
#16 | 10 | LGG | No | FGFR3(ex17)::TACC3(ex12) | Wildtype | Absent | PLGG | Group 3 | GG | LGG, GG | 0.89 | GG | 0.99 |
#17 | 38 | LGG | No | FGFR3(ex18)::TACC3(ex10) | Mutated | Present | GB IDH-WT | Group 3 | GG | LGG, GG | 0.59 | GG | 0.98 |
#18 | 13 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 1 | DNET | LGG, DNET | 0.6 | DNET | 0.77 |
#19 | 29 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 1 | DNET | LGG, DNET | 0.26 | RGNT | 0.28 |
#20 | 6 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 1 | DNET | LGG, DNET | 0.99 | DNET | 0.98 |
#21bis | 29 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 1 | DNET | LGG, DNET | 0.56 | MYXGNT, PDGFRA-mutant (novel) | 0.57 |
#22 | 1 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 1 | DNET | LGG, DNET | 0.48 | GG | 0.39 |